Abstract: A method for producing a resin sintered body 1 by applying an ink 3 to thermoplastic resin powder 2 and sintering the powder, the method including the step of immersing an intermediate resin sintered body 1m, which has an unevenly colored region on the surface thereof and the whole of which has been already sintered, in a surface treatment liquid containing sulfuric acid and chromic anhydride, in which the concentration of chromic anhydride is 300 g/L or more, for 5 minutes or longer. When producing a resin sintered body by sintering thermoplastic resin powder, the surface of the resin sintered body can be evenly and sufficiently colored to an extent required without an unevenly colored region on the surface thereof, and also the surface of the resin sintered body can have a good appearance and smoothness.

Abstract: A 1,4-benzodioxin derivative represented by formula (I) ##STR1## wherein A is an aryl group or a (C.sub.3 -C.sub.8)cycloalkyl group, R.sub.1 and R.sub.2 individually are a hydrogen atom, a halogen atom, an alkyl group, a trifluoromethyl group, an alkoxy group, an aryl group, an aryloxy group, or R.sub.1 and R.sub.2 together form a methylenedioxy group, R.sub.3 is a hydrogen atom or an alkyl group, R.sub.4 is a hydrogen atom or CO.sub.2 R.sub.5, R.sub.5 is a hydrogen atom or an alkyl group, X is a radical of formula (II) or (III) ##STR2## wherein n is 1 or 2. The compounds are useful for a prophylactic or therapeutic agent for diabetes, hyperglycemia and obesity.

Abstract: There is disclosed a multidrug resistance inhibitor for overcoming a multidrug resistance of cancer, or an agent for enhancing the activity of anti-cancer agents, which comprises as an active ingredient a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein n is an integer of 5 to 12,R.sub.1 and R.sub.2 are each independently benzyl, of which a phenyl ring may be substituted by 1 to 5 substituents selected from hydroxy, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy and halogen, and/or by methylenedioxy, with the proviso that R.sub.1 and R.sub.

Abstract: 9-Cis-retinoic acid-.alpha.-tocopherol esters, pharmaceutical compositions containing the same and use of the same as a medicine for the treatment of leukemia, in particular, the remission of leukemia are provided and a combined use of a 9-cis-retinoic acid-.alpha.-tocopherol ester and either 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid exhibits a synergistic effect in the treatment of leukemia without any side effects caused by 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid.

Abstract: 9-Cis-retinoic acid-.alpha.-tocopherol esters, pharmaceutical compositions containing the same and use of the same as a medicine for the treatment of leukemia, in particular, the remission of leukemia are provided and a combined use of a 9-cis-retinoic acid-.alpha.-tocopherol ester and either 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid exhibits a synergistic effect in the treatment of leukemia without any side effects caused by 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid.

Abstract: Isoprene derivatives of formula (I) ##STR1## wherein m is an integer of 0 to 3,n is an integer of 5 to 12,A is cyclo(C.sub.3 -C.sub.6)alkylene, phenylene, fluorenylene, pyrrolidinylene, piperazinylene, 9-aza-3-oxabicyclo?3.3.1!-nonylene,R.sub.1 and R.sub.2 are each independently benzyl, of which a phenyl ring may be substituted by 1 to 5 substituents selected from the group consisting of hydroxy, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy and halogen,X is a single bond or a divalent radical of --(CH.sub.2).sub.p NH--,p is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof. Those compounds are useful as multidrug resistance inhibitors for overcoming multidrug resistance of cancer and agents for enhancing an activity of anti-cancer agents.

Abstract: Novel diaminomethylidene derivatives represented by formula (I) ##STR1## wherein R.sup.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group and others, R.sup.2 is a group of the following formula ##STR2## and others, R.sup.3 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group and others, X is O, S, CHNO.sub.2, C(COOR.sup.4).sub.2, C(COOR.sup.4)CN or C(CN).sub.2) or pharmacologically acceptable salts thereof.The above-mentioned compounds are useful as a gastrointestinal prokinetic agent to be used for the treatment of digestive tract diseases.

Abstract: Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like;R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group;R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof.